antibody

Current Special Section SLIDER Special Section 

Against the Grain: The Cutting Edge of Migraine Treatments

December 1, 2020December 1, 2020 Jim Kelsey anti-CGRP, anti-CGRP monoclonal antibody, antibody, attention seek, Botox, Botox injection, brain stem, CGRP, chi, chi saint, Chumley, Chumley serve, clinical neurophysiology fellowship, clinical Neurophysiology lab, combination of genetics, cut edge of migraine treatment, director of the clinical Neurophysiology lab, disease condition, disorder of neuropeptides, Dr. Chumley, female migraine patient, Gil Dunn Warren Chumley, grade science project, grain, headache, history of stroke, image001 photo, injection, Joseph, Joseph health, Joseph medical group, Lexington, medical science liaison, medication, meninges, migraine, migraine patient, migraine treatment, monoclonal, national level meet, neurologist, neurology, neurology more thing, neurophysiology, neurophysiology fellowship, Neurophysiology lab, office hour see patient, patient age 18, radiologist father, science liaison, science project, therapy, track cross, treatment option, university of Kentucky college of medicine, Warren Chumley

LEXINGTON While many fourth graders find a science project to be nothing but a headache, Warren Chumley, MD, found it

Read more

News News & Events 

Tracking COVID-19 by Testing Louisville Health Care Workers

May 1, 2020June 1, 2020 MD-Update Staff antibody, Brad Shafer, careworkers, Co-Immunity, Co-Immunity project, Co-Immunity project 's goal, comprehensive coronavirus, coronavirus, coronavirus immunity, COVID-19, CPM, groundbreaking initiative, health careworkers, immunity, integral partner, integral partner of UofL, Jewish heritage fund, JHFE, JHFE board chair, level of immunity, Linda Schuster, Louisville, Louisville 's health care community, Louisville Christina Lee Brown Envirome, Louisville Christina Lee Brown Envirome institute, Louisville health system, Louisville Healthcare CEO, Louisville Healthcare CEO council, Louisville healthcare worker, major health system, Norton Healthcare, real-time picture, real-time picture of the virus, university of Louisville Christina Lee Brown Envirome institute, UofL, UofL health, UofL vice president, virus, wave of COVID-19, world focus

LOUISVILLE Just as the Co-Immunity Project began its first phase to test Louisville healthcare workers for COVID-19 and antibodies from

Read more

Special Section 

Stimulating the Immune System to Attack Cancer

October 1, 2019December 9, 2019 MD-Update Staff antibody, associate VP, associate VP of health affair, brake, budget, cancer, cancer cell, cancer institute, cancer research, cancer-related, cancer-related death, carcinoma, cell carcinoma, checkpoint, checkpoint inhibitor, Chesney, Chesney 's research, cytotoxic, Cytotoxic T cell, defense budget, director of the UofL James Graham Brown cancer center, health affair, immune checkpoint inhibitor, immune system, immunotherapy, inhibitor, JGBCC, Louisville Jason Chesney, melanoma, national cancer institute, NCI, oncolytic, oncolytic virus, PhD, T, T cell, TVEC, U.S. budget, UofL, UofL Brown, UofL Brown cancer center, UofL James Graham Brown, UofL James Graham Brown cancer center, UofL researcher test, virus, VP

LOUISVILLE Jason Chesney, MD, PhD, is the director of the UofL James Graham Brown Cancer Center (JGBCC) and associate VP

Read more

Special Section 

Reshaping Remission

October 1, 2017 Jennifer S. Newton acute leukemia, adult leukemia, Albany, antibody, antibody therapy, baptist health, baptist health cancer, bone, bone marrow transplant, cancer, chemotherapy, Chowhan, chronic leukemia, chronic myeloid leukemia, director of medical oncology, genetic mutation, good response rate, health cancer, hematologist, IND, landscape of treatment, leukemia, line treatment, marrow, medical oncology, mutation, myeloid, myeloid leukemia, NCI, new Albany, new class, oncologist, oncology, remission, reshape remission, response rate, standard treatment, survival, survival rate, therapy, TKIs, transplant

NEW ALBANY, IND Say the word “leukemia,” and many people will immediately think of childhood cancer. But, according to the

Read more

Gastroenterology Internal Systems Special Section 

Killing It Softly

November 1, 2015July 17, 2017 Jim Kelsey American society of hematology, antibody, awareness change, benign hematology patient, bone, bortezomib, cancer, cancer treatment, chemotherapy, chemotherapy cause patient, death sentence, Dr. Jessica Croley, experience nausea, hematologic malignancy, hematology, hematology patient, ibrutinib, Jessica Moss, joint practice, KentuckyOne, KentuckyOne cancer center umbrella, KentuckyOne health, KentuckyOne health hematology, lenalidomide, Louisville medical school, lymphoma, machete, major splash, medical breakthrough, misconception, Moss, myeloma, nausea, new cancer treatment, oncologist, oncology, oncology associate, oncology fellowship, oncology patient, oncology rotation, outpatient-based, pediatrics practice, physician, plasma, plasma cell, prognosis, prominent discussion topic, protein, public awareness change, scalpel, scalpel analogy, small community practice, surface of cancer cell, targeted agent, targeted drug, toxicity, toxicity of chemotherapy cause patient, traditional chemotherapy, university of Louisville medical school, visit patient

LEXINGTON “It’s like using a scalpel instead of a machete.” We are used to seeing medical breakthroughs make a major

Read more

Special Section 

The Challenges of Aplastic Anemia

September 1, 2015February 1, 2017 Jill Debolt Allergy & Immunology, anemia, antibody, Aplastic, Aplastic anemia, aplastic anemia case, ATG, B cell, blood cell, bone, bone marrow, bone marrow activity, cancer, cell aplasia, cell progenitor, challenge area, challenge of Aplastic anemia, clinical practice, clinical research, complex blood disorder, decreased red blood cell count, donor, example of red cell aplasia, hematology, hematology specialist, hematopoietic, hematopoietic stem cell, hematopoietic stem cell line, hepatitis, hepatitis aplastic anemia, human B cell, immune system, immunosuppressive therapy, immunotherapy, incidence of two-to-four case, infection, KentuckyOne, KentuckyOne health, khan, Khuda, Khuda khan, Louisville Aplastic, Louisville Aplastic anemia, lung cancer, marrow, moderate aplastic anemia, new immunotherapy, note khan, oncology, oncology specialist, overwhelm infection, pancytopenia, PhD. khan, platelet, platelet count, prognosis, rare disease of the hematopoietic stem cell, red cell aplasia, red cell progenitor, scientific knowledge of the immune system, severity of aplastic anemia, specialist, spontaneous bleed, state khan, stem, stem cell transplant, suitable donor, supportive care, therapy, transfusion, transplant, treatment therapy, two-to-four case, viral hepatitis aplastic anemia, white blood cell

LOUISVILLE Aplastic anemia is a complex, relatively rare disease of the hematopoietic stem cells in the bone marrow, according to

Read more

Cancer Care Cover Story Oncology 

Game Changer

July 1, 2014July 17, 2017 Jennifer S. Newton 30 to 40 % response rate, A., antibody, autoimmune, Bristol-Myers Squibb, broad clinical trial program, brown cancer center, cancer, cancer center, cancer patient, carcinoma, cell carcinoma, changer, checkpoint, checkpoint protein, Chesney, clinical trial, clinical trial center, community oncology center, CTLA-4, dose-escalation, Dr. Jason Chesney, early access, FDA, FDA approval, FDA-approved, FDA-approved drug, game changer, health care access, immune checkpoint protein, immune system, immunotherapy, imperative message, improvement, infusion, inhibitor, ipilimumab, Ipilimumab work, James Graham Brown, James Graham Brown cancer center deputy director, Jason A., Kentucky, KentuckyOne, KentuckyOne health, Louisville university, Louisville university of Louisville 's, lung, lung cancer, melanoma, melanoma patient, Merck, new class, new class of drug, Nivolumab, oncology, overall survival, patient access, PD-1, PD-1 inhibitor, PD-L1, pembrolizumab, PFK-158, phase 1/2, phase 1/2 dose-escalation trial, pretty compel, protein, renal cell carcinoma, response rate, stage 4, stage 4 cancer, stage 4 melanoma, stage 4 melanoma patient, standard FDA-approved drug, survival, survival data, survival rate, therapy, trial center, tumor, U, Yervoy®

LOUISVILLE University of Louisville’s (U of L) James Graham Brown Cancer Center Deputy Director Jason A. Chesney, MD, PhD, has

Read more

Special Section 

Family Allergy & Asthma

August 1, 2012February 1, 2017 Jennifer S. Newton allergist, allergy, Allergy & Immunology, allergy practice, antibiotic, antibody, APRN, Arora, asthma, asthma 's Lexington office, asthmatic patient population, atypical infection, avoidance measure, care physician treat asthmatics, deficiency, deficiency patient, early thing, educate patient, equal mix of child, family allergy, full-time, full-time coverage, good control of symptom, guide principal, hallmark of asthma, high level of quality patient, hub office, immune deficiency, immune deficiency patient, immune system, immunotherapy, infection, inflammation of the airway, inhalant, inhalant allergy, inhaler, intradermal test, irony of medical practice, J., L., Lexington, Lexington imagine, Lexington office, Louisville, Louisville 's east end, manage partner, manage partner of family allergy, medication, monitor asthma, nurse, nurse practitioner, office site, one-in-four, one-in-four people, outdoor inhalant allergy, patient allergist, people call sinus problem, physician, potential allergic trigger, practitioner, prick skin test, primary care physician treat asthmatics, proper use of medication, provider, quality patient, Rajiv Arora, satellite office branch, service family allergy, specialty service, sub-hubs, Sublett, three-legged approach, two-thirds of people, typical antibiotic, use of provider, year-round allergy

LOUISVILLE, LEXINGTON Imagine needing to buy milk, but when you get to the grocery store they tell you the product

Read more